Global Expansion Celt ACD has both EU and US adoption with over 30,000 patient implants, indicating strong international market traction and potential for further geographic expansion and channel partnerships.

Clinical Validation PMA and CE Mark approvals plus multi-size availability (5F, 6F, 7F) suggest credibility with vascular surgeons and interventional teams, opening doors for trials, KOL engagement, and hospital procurement programs.

M&A Readiness Growing investor interest and a recent €7.3M funding round highlight Vasorum as a scalable platform for strategic partnerships, licensing deals, or acquisition conversations with larger medical device players.

Product Differentiation Unique dual-sided biocompatible implant and no sheath exchange during deployment position Celt ACD as a time-saving, patient-friendly closure solution, suitable for sales pitches to hospitals aiming to reduce procedure time and complications.

Strategic Partnerships Presence of a senior non-executive director and a US market expansion footprint imply opportunities to collaborate with distributors, group purchasing organizations, and vascular access program managers in both EU and US markets.